Your browser doesn't support javascript.
loading
Low-dose azithromycin prophylaxis in patients with atrial fibrillation and chronic obstructive pulmonary disease.
Bucci, Tommaso; Wat, Dennis; Sibley, Sarah; Wootton, Dan; Green, David; Pignatelli, Pasquale; Lip, Gregory Y H; Frost, Freddy.
Afiliación
  • Bucci T; Liverpool Centre for Cardiovascular Science at University of Liverpool, Liverpool John Moores University and Liverpool Heart & Chest Hospital, Liverpool, UK.
  • Wat D; Department of Clinical Internal, Anesthesiological and Cardiovascular Sciences, Sapienza University of Rome, Rome, Italy.
  • Sibley S; Liverpool Centre for Cardiovascular Science at University of Liverpool, Liverpool John Moores University and Liverpool Heart & Chest Hospital, Liverpool, UK.
  • Wootton D; Knowsley Community Respiratory Service, Liverpool Heart & Chest Hospital NHS Foundation Trust, Liverpool, UK.
  • Green D; Knowsley Community Respiratory Service, Liverpool Heart & Chest Hospital NHS Foundation Trust, Liverpool, UK.
  • Pignatelli P; Respiratory Department, Liverpool University Hospital NHS Foundation Trust, Liverpool, UK.
  • Lip GYH; Institute of Infection, Veterinary and Ecological Sciences, University of Liverpool, Liverpool, UK.
  • Frost F; Knowsley Community Respiratory Service, Liverpool Heart & Chest Hospital NHS Foundation Trust, Liverpool, UK.
Intern Emerg Med ; 19(6): 1615-1623, 2024 Sep.
Article en En | MEDLINE | ID: mdl-38819711
ABSTRACT
Low-dose azithromycin prophylaxis is associated with improved outcomes in people suffering frequent exacerbations of chronic obstructive pulmonary disease (COPD), but the use of macrolides in patients with cardiovascular disease has been debated. To investigate the risk of adverse events after COPD exacerbations in patients with atrial fibrillation (AF) treated with azithromycin prophylaxis. Retrospective cohort study within the TriNetX Platform, including AF patients with COPD exacerbations. Risks of primary and secondary outcomes were recorded up to 30 days post-COPD exacerbations and compared between azithromycin users and azithromycin non-users. The primary outcomes were the risks for a composite of (1) cardiovascular (all-cause death, heart failure, ventricular arrhythmias, ischemic stroke, myocardial infarction, and cardiac arrest), and (2) hemorrhagic events (intracranial hemorrhage (ICH), and gastro-intestinal bleeding). Cox-regression analyses compared outcomes between groups after propensity score matching (PSM). After PSM, azithromycin users (n = 2434, 71 ± 10 years, 49% females) were associated with a lower 30-day risk of post-exacerbation cardiovascular (HR 0.67, 95% CI 0.61-0.73) and hemorrhagic composite outcome (HR 0.45, 95% CI 0.32-0.64) compared to azithromycin non-users (n = 2434, 72 ± 11 years, 51% females). The beneficial effect was consistent for each secondary outcomes, except ICH. On sensitivity analyses, the reduced risk of adverse events in azithromycin users was irrespective of smoking status, exacerbation severity, and type of oral anticoagulation. Azithromycin prophylaxis is associated with a lower risk of all-cause death, thrombotic and hemorrhagic events in AF patients with COPD. The possible role of azithromycin prophylaxis as part of the integrated care management of AF patients with COPD needs further study.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Fibrilación Atrial / Azitromicina / Enfermedad Pulmonar Obstructiva Crónica / Antibacterianos Límite: Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Revista: Intern Emerg Med Asunto de la revista: MEDICINA DE EMERGENCIA / MEDICINA INTERNA Año: 2024 Tipo del documento: Article País de afiliación: Reino Unido Pais de publicación: Italia

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Fibrilación Atrial / Azitromicina / Enfermedad Pulmonar Obstructiva Crónica / Antibacterianos Límite: Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Revista: Intern Emerg Med Asunto de la revista: MEDICINA DE EMERGENCIA / MEDICINA INTERNA Año: 2024 Tipo del documento: Article País de afiliación: Reino Unido Pais de publicación: Italia